Last reviewed · How we verify
TARPEYO®
At a glance
| Generic name | TARPEYO® |
|---|---|
| Also known as | delayed-release budesonide capsules |
| Sponsor | Calliditas Therapeutics AB |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
- Peripheral edema
- Hypertension
- Muscle spasms
- Acne
- Headache
- Upper respiratory tract infection
- Face edema
- Weight increased
- Dyspepsia
- Dermatitis
- Arthralgia
- White blood cell count increased
Serious adverse events
- Hypercortisolism
- Adrenal axis suppression
- Immunosuppression
Key clinical trials
- Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy (PHASE4)
- Relative Bioavailability Study of HR19042 in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TARPEYO® CI brief — competitive landscape report
- TARPEYO® updates RSS · CI watch RSS
- Calliditas Therapeutics AB portfolio CI